{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:29:44Z","timestamp":1793852984763,"version":"4.6.1"},"reference-count":149,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009250","name":"National Institute for Social Care and Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009250","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.molmed.2025.08.009","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T03:44:38Z","timestamp":1758599078000},"page":"385-398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Migraine: advances in treatment"],"prefix":"10.1016","volume":"32","author":[{"given":"Usman","family":"Ashraf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3260-5904","authenticated-orcid":false,"given":"Peter J.","family":"Goadsby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2025.08.009_bb0005","first-page":"1","article-title":"The International Classification of Headache Disorders, 3rd edition","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","journal-title":"Cephalalgia"},{"key":"10.1016\/j.molmed.2025.08.009_bb0010","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41572-021-00328-4","article-title":"Migraine","volume":"8","author":"Ferrari","year":"2022","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.molmed.2025.08.009_bb0015","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","article-title":"Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019","volume":"21","author":"Steiner","year":"2020","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.molmed.2025.08.009_bb0020","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s10194-023-01552-x","article-title":"Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience","volume":"24","author":"Raffaelli","year":"2023","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.molmed.2025.08.009_bb0025","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1152\/physrev.00034.2015","article-title":"Pathophysiology of migraine: a disorder of sensory processing","volume":"97","author":"Goadsby","year":"2017","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.molmed.2025.08.009_bb0030","doi-asserted-by":"crossref","first-page":"8827","DOI":"10.1523\/JNEUROSCI.0439-13.2013","article-title":"Paraventricular hypothalamic regulation of trigeminovascular mechanisms involved in headaches","volume":"33","author":"Robert","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.molmed.2025.08.009_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0167-0115(86)90071-6","article-title":"Calcitonin gene-related peptide (CGRP): perivascular distribution and vasodilatory effects","volume":"15","author":"Uddman","year":"1986","journal-title":"Regul. Pept."},{"key":"10.1016\/j.molmed.2025.08.009_bb0040","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/304129a0","article-title":"Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing","volume":"304","author":"Rosenfeld","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2025.08.009_bb0045","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ana.410330109","article-title":"The trigeminovascular system and migraine \u2013 studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats","volume":"33","author":"Goadsby","year":"1993","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.molmed.2025.08.009_bb0050","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ana.410230214","article-title":"Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system","volume":"23","author":"Goadsby","year":"1988","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.molmed.2025.08.009_bb0055","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/ana.410280213","article-title":"Vasoactive peptide release in the extracerebral circulation of humans during migraine headache","volume":"28","author":"Goadsby","year":"1990","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.molmed.2025.08.009_bb0060","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/14728222.2020.1724285","article-title":"Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting","volume":"24","author":"Wattiez","year":"2020","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.molmed.2025.08.009_bb0065","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1046\/j.1468-2982.2002.00310.x","article-title":"CGRP may play a causative role in migraine","volume":"22","author":"Lassen","year":"2002","journal-title":"Cephalalgia"},{"key":"10.1016\/j.molmed.2025.08.009_bb0070","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1177\/0333102410368444","article-title":"Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura","volume":"30","author":"Hansen","year":"2010","journal-title":"Cephalalgia"},{"key":"10.1016\/j.molmed.2025.08.009_bb0075","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1152\/physrev.00059.2021","article-title":"CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond","volume":"103","author":"Russo","year":"2023","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.molmed.2025.08.009_bb0080","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1042\/bst0300460","article-title":"Receptor component protein (RCP): a member of a multi-protein complex required for G-protein-coupled signal transduction","volume":"30","author":"Prado","year":"2002","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.molmed.2025.08.009_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173205","article-title":"The effects of CGRP in vascular tissue \u2013 classical vasodilation, shadowed effects and systemic dilemmas","volume":"881","author":"Sohn","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.molmed.2025.08.009_bb0090","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1212\/WNL.0000000000000771","article-title":"Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention","volume":"83","author":"Ho","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.molmed.2025.08.009_bb0095","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1177\/0333102411398399","article-title":"Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine","volume":"31","author":"Hewitt","year":"2011","journal-title":"Cephalalgia"},{"key":"10.1016\/j.molmed.2025.08.009_bb0100","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/toxsci\/kfac051","article-title":"Comparing the liver safety profiles of 4 next-generation CGRP receptor antagonists to the hepatotoxic CGRP inhibitor telcagepant using quantitative systems toxicology modeling","volume":"188","author":"Woodhead","year":"2022","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.molmed.2025.08.009_bb0105","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa030505","article-title":"Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine","volume":"350","author":"Olesen","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2025.08.009_bb0110","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","article-title":"Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial","volume":"397","author":"Croop","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2025.08.009_bb0115","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1056\/NEJMoa2035908","article-title":"Atogepant for the preventive treatment of migraine","volume":"385","author":"Ailani","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2025.08.009_bb0120","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","article-title":"Ubrogepant for the treatment of migraine","volume":"381","author":"Dodick","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2025.08.009_bb0125","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1001\/jama.2019.16711","article-title":"Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial","volume":"322","author":"Lipton","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.molmed.2025.08.009_bb0130","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1474-4422(20)30234-9","article-title":"Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b\/3 trial","volume":"19","author":"Goadsby","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.molmed.2025.08.009_bb0135","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s10194-019-0979-y","article-title":"CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?","volume":"20","author":"Favoni","year":"2019","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.molmed.2025.08.009_bb0140","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1177\/03331024211000311","article-title":"Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II","volume":"41","author":"Hutchinson","year":"2021","journal-title":"Cephalalgia"},{"key":"10.1016\/j.molmed.2025.08.009_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00228-007-0391-4","article-title":"Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients: relation with serotonin levels","volume":"64","author":"Rossi","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.molmed.2025.08.009_bb0150","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s10194-024-01755-w","article-title":"Medication-overuse headache: a narrative review","volume":"25","author":"Gosalia","year":"2024","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.molmed.2025.08.009_bb0155","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/0006-291X(89)91757-9","article-title":"Isolation of a novel-38 residue-hypothalamic polypeptide which stimulates adenylate-cyclase in pituitary-cells","volume":"164","author":"Miyata","year":"1989","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.molmed.2025.08.009_bb0160","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s10194-018-0845-3","article-title":"Protective effects of PACAP in ischemia","volume":"19","author":"Reglodi","year":"2018","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.molmed.2025.08.009_bb0165","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1177\/0333102413483931","article-title":"Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients","volume":"33","author":"Tuka","year":"2013","journal-title":"Cephalalgia"},{"key":"10.1016\/j.molmed.2025.08.009_bb0170","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/acn3.113","article-title":"Pituitary adenylate cyclase activating polypeptide and migraine","volume":"1","author":"Zagami","year":"2014","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.molmed.2025.08.009_bb0175","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.peptides.2008.01.022","article-title":"Novel stable PACAP analogs with potent activity towards the PAC1 receptor","volume":"29","author":"Bourgault","year":"2008","journal-title":"Peptides"},{"key":"10.1016\/j.molmed.2025.08.009_bb0180","series-title":"DPP-4 is better target to lower migraine rates in patients with type 2 diabetes. European Headache Congress 2024","author":"Ting-Chuan","year":"2024"},{"key":"10.1016\/j.molmed.2025.08.009_bb0185","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1385\/JMN:27:1:091","article-title":"Signaling cascades involved in neuroprotection by subpicomolar pituitary adenylate cyclase-activating polypeptide 38","volume":"27","author":"Li","year":"2005","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.molmed.2025.08.009_bb0190","first-page":"99","article-title":"PACAP inhibition alleviates neuropathic pain by modulating Nav1.7 through the MAPK\/ERK signaling pathway in a rat model of chronic constriction injury","author":"Liu","year":"2023","journal-title":"Neuropeptides"},{"key":"10.1016\/j.molmed.2025.08.009_bb0195","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1097\/j.pain.0000000000000702","article-title":"Premonitory and nonheadache symptoms induced by CGRP and PACAP38 in patients with migraine","volume":"157","author":"Guo","year":"2016","journal-title":"Pain"},{"key":"10.1016\/j.molmed.2025.08.009_bb0200","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.tips.2023.07.003","article-title":"Calcitonin\/PAC(1) receptor splice variants: a blind spot in migraine research","volume":"44","author":"Rees","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.molmed.2025.08.009_bb0205","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa2314577","article-title":"A monoclonal antibody to PACAP for migraine prevention","volume":"391","author":"Ashina","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2025.08.009_bb0210","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.cell.2019.10.010","article-title":"Discovery of human signaling systems: pairing peptides to G protein-coupled receptors","volume":"179","author":"Foster","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2025.08.009_bb0215","doi-asserted-by":"crossref","first-page":"13328","DOI":"10.3390\/ijms222413328","article-title":"Gene expression data mining reveals the involvement of GPR55 and its endogenous ligands in immune response, cancer, and differentiation","volume":"22","author":"Wnorowski","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.molmed.2025.08.009_bb0220","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2174\/1570159X14666160729155441","article-title":"Advances in the physiology of GPR55 in the central nervous system","volume":"15","author":"Marichal-Cancino","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.molmed.2025.08.009_bb0225","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.pain.2008.04.006","article-title":"The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain","volume":"139","author":"Staton","year":"2008","journal-title":"Pain"},{"key":"10.1016\/j.molmed.2025.08.009_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105743","article-title":"The neuroprotective effects of GPR55 against hippocampal neuroinflammation and impaired adult neurogenesis in CSDS mice","volume":"169","author":"Shen","year":"2022","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.molmed.2025.08.009_bb0235","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1463-1326.2011.01515.x","article-title":"The atypical cannabinoid O-1602 stimulates food intake and adiposity in rats","volume":"14","author":"Diaz-Arteaga","year":"2012","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.molmed.2025.08.009_bb0240","doi-asserted-by":"crossref","first-page":"12302","DOI":"10.1038\/s41598-023-39571-y","article-title":"PACAP activates MRGPRX2 on meningeal mast cells to drive migraine-like pain","volume":"13","author":"Sbei","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2025.08.009_bb0245","doi-asserted-by":"crossref","DOI":"10.1177\/17448069231181358","article-title":"Roles of mast cells and their interactions with the trigeminal nerve in migraine headache","volume":"19","author":"Guan","year":"2023","journal-title":"Mol. Pain"},{"key":"10.1016\/j.molmed.2025.08.009_bb0250","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1007\/s12031-021-01821-x","article-title":"PAC1 receptor internalization and endosomal MEK\/ERK activation is essential for PACAP-mediated neuronal excitability","volume":"71","author":"May","year":"2021","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.molmed.2025.08.009_bb0255","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.peptides.2011.05.022","article-title":"Shared and separate functions of the RAMP-based adrenomedullin receptors","volume":"32","author":"Kuwasako","year":"2011","journal-title":"Peptides"},{"key":"10.1016\/j.molmed.2025.08.009_bb0260","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.4103\/1673-5374.272567","article-title":"Adrenomedullin: an important participant in neurological diseases","volume":"15","author":"Li","year":"2020","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.molmed.2025.08.009_bb0265","doi-asserted-by":"crossref","first-page":"16027","DOI":"10.1073\/pnas.0602488103","article-title":"A role for adrenomedullin as a pain-related peptide in the rat","volume":"103","author":"Ma","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2025.08.009_bb0270","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000011930","article-title":"Effect of adrenomedullin on migraine-like attacks in patients with migraine: a randomized crossover study","volume":"96","author":"Ghanizada","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.molmed.2025.08.009_bb0275","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1042\/bst0300432","article-title":"Adrenomedullin: receptor and signal transduction","volume":"30","author":"Smith","year":"2002","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.molmed.2025.08.009_bb0280","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s10194-024-01863-7","article-title":"Differential expression of components of the CGRP-receptor family in human coronary and human middle meningeal arteries: functional implications","volume":"25","author":"de Vries","year":"2024","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.molmed.2025.08.009_bb0285","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1146\/annurev-pharmtox-010715-103120","article-title":"Receptor activity-modifying proteins (RAMPs): new insights and roles","volume":"56","author":"Hay","year":"2016","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.molmed.2025.08.009_bb0290","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.860037","article-title":"CGRP and the calcitonin receptor are co-expressed in mouse, rat and human trigeminal ganglia neurons","volume":"13","author":"Rees","year":"2022","journal-title":"Front. Physiol."},{"key":"10.1016\/j.molmed.2025.08.009_bb0295","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/ana.26072","article-title":"Amylin analog pramlintide induces migraine-like attacks in patients","volume":"89","author":"Ghanizada","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.molmed.2025.08.009_bb0300","doi-asserted-by":"crossref","first-page":"47S","DOI":"10.1177\/0145721715607642","article-title":"Role of amylin in type 1 and type 2 diabetes","volume":"41","author":"Hieronymus","year":"2015","journal-title":"Diabetes Educ."},{"key":"10.1016\/j.molmed.2025.08.009_bb0305","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1526-4610.2004.04078.x","article-title":"Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine","volume":"44","author":"Dodick","year":"2004","journal-title":"Headache"},{"key":"10.1016\/j.molmed.2025.08.009_bb0310","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1001\/jamaneurol.2023.5549","article-title":"Risk of stroke and myocardial infarction among initiators of triptans","volume":"81","author":"Petersen","year":"2024","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.molmed.2025.08.009_bb0315","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/s41582-023-00842-x","article-title":"The 5-HT receptor as the target of ditans in migraine - from bench to bedside","volume":"19","author":"Mitsikostas","year":"2023","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.molmed.2025.08.009_bb0320","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0306-4522(03)00570-0","article-title":"Evidence for serotonin (5-HT)1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input","volume":"122","author":"Goadsby","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.molmed.2025.08.009_bb0325","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1073\/pnas.90.2.408","article-title":"Cloning of another human serotonin receptor (5-Ht1f) - a 5th 5-Ht1 receptor subtype coupled to the inhibition of adenylate-cyclase","volume":"90","author":"Adham","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2025.08.009_bb0330","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1177\/0333102421989232","article-title":"Randomized, controlled trial of lasmiditan over four migraine attacks: findings from the CENTURION study","volume":"41","author":"Ashina","year":"2021","journal-title":"Cephalalgia"},{"key":"10.1016\/j.molmed.2025.08.009_bb0335","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/brain\/awz134","article-title":"Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine","volume":"142","author":"Goadsby","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.molmed.2025.08.009_bb0340","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000006641","article-title":"Lasmiditan is an effective acute treatment for migraine A phase 3 randomized study","volume":"91","author":"Kuca","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.molmed.2025.08.009_bb0345","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/s42003-024-06299-y","article-title":"Genome-wide association study reveals a locus in ADARB2 for complete freedom from headache in Danish blood donors","volume":"7","author":"Olofsson","year":"2024","journal-title":"Commun. Biol."},{"key":"10.1016\/j.molmed.2025.08.009_bb0350","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/j.1601-183X.2011.00701.x","article-title":"Altered ADAR 2 equilibrium and 5HT(2C) R editing in the prefrontal cortex of ADAR 2 transgenic mice","volume":"10","author":"Singh","year":"2011","journal-title":"Genes Brain Behav."},{"key":"10.1016\/j.molmed.2025.08.009_bb0355","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/2045125315584869","article-title":"Agomelatine and migraine management: a successfully treated case series","volume":"5","author":"Plasencia-Garcia","year":"2015","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.molmed.2025.08.009_bb0360","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.bjp.0705437","article-title":"Agonist actions of dihydroergotamine at 5-HT and 5-HT receptors and their possible relevance to antimigraine efficacy","volume":"140","author":"Schaerlinger","year":"2003","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.molmed.2025.08.009_bb0365","doi-asserted-by":"crossref","first-page":"17498","DOI":"10.1074\/jbc.273.28.17498","article-title":"Cross-talk between 5-hydroxytryptamine receptors in a serotonergic cell line - involvement of arachidonic acid metabolism","volume":"273","author":"Tournois","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2025.08.009_bb0370","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s13311-020-00962-y","article-title":"Exploratory controlled study of the migraine-suppressing effects of psilocybin","volume":"18","author":"Schindler","year":"2021","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.molmed.2025.08.009_bb0375","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.biochi.2018.10.015","article-title":"The 5-HT1A receptor: signaling to behavior","volume":"161","author":"Albert","year":"2019","journal-title":"Biochimie"},{"key":"10.1016\/j.molmed.2025.08.009_bb0380","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0009-9236(95)90161-2","article-title":"Buspirone, but not sumatriptan, induces miosis in humans: relevance for a serotoninergic pupil control","volume":"57","author":"Fanciullacci","year":"1995","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.molmed.2025.08.009_bb0385","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1177\/0333102410385581","article-title":"Brainstem changes in 5-HT1A receptor availability during migraine attack","volume":"31","author":"Demarquay","year":"2011","journal-title":"Cephalalgia"},{"key":"10.1016\/j.molmed.2025.08.009_bb0390","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1046\/j.1468-2982.2003.00441.x","article-title":"Central 5-HT receptor hypersensitivity in migraine without aura","volume":"23","author":"Cassidy","year":"2003","journal-title":"Cephalalgia"},{"key":"10.1016\/j.molmed.2025.08.009_bb0395","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/BF01257081","article-title":"5-HT1A receptor function in depression: effect of chronic amitriptyline treatment","volume":"80","author":"Lesch","year":"1990","journal-title":"J. Neural Transm. Gen. Sect."},{"key":"10.1016\/j.molmed.2025.08.009_bb0400","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1016\/S0014-2999(99)00517-8","article-title":"Valproate and carbamazepine increase prefrontal dopamine release by 5-HT1A receptor activation","volume":"380","author":"Ichikawa","year":"1999","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.molmed.2025.08.009_bb0405","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00008877-199807000-00002","article-title":"Antidepressant-like effects of 5-hydroxytryptamine1A receptor agonists on operant responding under a response duration differentiation schedule","volume":"9","author":"Kinney","year":"1998","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.molmed.2025.08.009_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2021.136380","article-title":"The role of TRP ion channels in migraine and headache","volume":"768","author":"Iannone","year":"2022","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.molmed.2025.08.009_bb0415","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s11481-018-9796-3","article-title":"Ethanol\u2019s effects on transient receptor potential channel expression in brain microvascular endothelial cells","volume":"13","author":"Chang","year":"2018","journal-title":"J. NeuroImmune Pharmacol."},{"key":"10.1016\/j.molmed.2025.08.009_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/S1090-3801(09)60705-9","article-title":"702 A randomised, two-period cross-over study to investigate the efficacy of the TRPV1 antagonist SB-705498 in acute migraine [abstract]","volume":"13","author":"Chizh","year":"2009","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.molmed.2025.08.009_bb0425","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/ng.2307","article-title":"Genome-wide association analysis identifies susceptibility loci for migraine without aura","volume":"44","author":"Freilinger","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.molmed.2025.08.009_bb0430","doi-asserted-by":"crossref","first-page":"6304","DOI":"10.1038\/s41467-022-33835-3","article-title":"TRPM8 contributes to sex dimorphism by promoting recovery of normal sensitivity in a mouse model of chronic migraine","volume":"13","author":"Alarcon-Alarcon","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2025.08.009_bb0435","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fneur.2015.00011","article-title":"Efficacy and tolerability of STOPAIN for a migraine attack","volume":"6","author":"St Cyr","year":"2015","journal-title":"Front. Neurol."},{"key":"10.1016\/j.molmed.2025.08.009_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114310","article-title":"The TRPM3 ion channel mediates nociception but not itch evoked by endogenous pruritogenic mediators","volume":"183","author":"Kelemen","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.molmed.2025.08.009_bb0445","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2023.1182515","article-title":"The ATP sensitive potassium channel (K) is a novel target for migraine drug development","volume":"16","author":"Clement","year":"2023","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.molmed.2025.08.009_bb0450","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1093\/brain\/awab136","article-title":"Opening of ATP sensitive potassium channels causes migraine attacks with aura","volume":"144","author":"Al-Karagholi","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.molmed.2025.08.009_bb0455","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1111\/head.13634","article-title":"Levcromakalim, an adenosine triphosphate-sensitive potassium channel opener, dilates extracerebral but not cerebral arteries","volume":"59","author":"Al-Karagholi","year":"2019","journal-title":"Headache"},{"key":"10.1016\/j.molmed.2025.08.009_bb0460","doi-asserted-by":"crossref","DOI":"10.1080\/19336950.2024.2398565","article-title":"Characterization of four structurally diverse inhibitors of SUR2-containing K(ATP) channels","volume":"18","author":"Li","year":"2024","journal-title":"Channels (Austin)"},{"key":"10.1016\/j.molmed.2025.08.009_bb0465","first-page":"205","article-title":"Non-vascular ATP-sensitive potassium channel activation does not trigger migraine attacks: a randomized clinical trial","volume":"43","author":"Kokoti","year":"2023","journal-title":"Cephalalgia"},{"key":"10.1016\/j.molmed.2025.08.009_bb0470","first-page":"43","article-title":"The effect of KATP channel blocker glibenclamide on CGRP-induced headache and hemodynamic in healthy volunteers","volume":"22","author":"Coskun","year":"2021","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.molmed.2025.08.009_bb0475","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s13311-023-01350-y","article-title":"Glibenclamide posttreatment does not inhibit levcromakalim induced headache in healthy participants: a randomized clinical trial","volume":"20","author":"Kokoti","year":"2023","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.molmed.2025.08.009_bb0480","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1161\/CIRCRESAHA.112.300514","article-title":"K channels and cardiovascular disease suddenly a syndrome","volume":"112","author":"Nichols","year":"2013","journal-title":"Circ. Res."},{"key":"10.1016\/j.molmed.2025.08.009_bb0485","first-page":"793","article-title":"The effects of nitrogylcerin upon those who manufacture it","volume":"31","author":"Laws","year":"1898","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"10.1016\/j.molmed.2025.08.009_bb0490","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1468-1331.1994.tb00053.x","article-title":"A nitric oxide donor (nitroglycerin) triggers genuine migraine attacks","volume":"1","author":"Thomsen","year":"1994","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.molmed.2025.08.009_bb0495","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.pain.2004.05.007","article-title":"Glyceryl trinitrate triggers premonitory symptoms in migraineurs","volume":"110","author":"Afridi","year":"2004","journal-title":"Pain"},{"key":"10.1016\/j.molmed.2025.08.009_bb0500","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10557-016-6668-z","article-title":"Vasodilator therapy: nitrates and nicorandil","volume":"30","author":"Tarkin","year":"2016","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.molmed.2025.08.009_bb0505","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2174\/157015911798376271","article-title":"cGMP signaling, phosphodiesterases and major depressive disorder","volume":"9","author":"Reierson","year":"2011","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.molmed.2025.08.009_bb0510","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00424-013-1373-2","article-title":"New perspectives in cyclic nucleotide-mediated functions in the CNS: the emerging role of cyclic nucleotide-gated (CNG) channels","volume":"466","author":"Podda","year":"2014","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.molmed.2025.08.009_bb0515","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s13311-018-0614-7","article-title":"Targeted nitric oxide synthase inhibitors for migraine","volume":"15","author":"Pradhan","year":"2018","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.molmed.2025.08.009_bb0520","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0140-6736(97)80021-9","article-title":"Nitric oxide synthase inhibition in migraine","volume":"349","author":"Lassen","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2025.08.009_bb0525","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1177\/0333102410370875","article-title":"Lack of efficacy of the selective iNOS inhibitor GW274150 in prophylaxis of migraine headache","volume":"30","author":"Hoivik","year":"2010","journal-title":"Cephalalgia"},{"key":"10.1016\/j.molmed.2025.08.009_bb0530","article-title":"A randomised, single-blind, placebo-controlled, adaptive clinical trial of GW274150, a selective iNOS inhibitor, in the treatment of acute migraine","volume":"29","author":"Palmer","year":"2009","journal-title":"Cephalalgia"},{"key":"10.1016\/j.molmed.2025.08.009_bb0535","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/eurheartj\/ehr304","article-title":"Nitric oxide synthases: regulation and function","volume":"33","author":"Forstermann","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.molmed.2025.08.009_bb0540","doi-asserted-by":"crossref","first-page":"ra68","DOI":"10.1126\/scisignal.aaa4312","article-title":"Regulation of brain glutamate metabolism by nitric oxide and S-nitrosylation","volume":"8","author":"Raju","year":"2015","journal-title":"Sci. Signal."},{"key":"10.1016\/j.molmed.2025.08.009_bb0545","article-title":"L-NAME reduces fos expression in trigemino-cervical complex after superior sagittal sinus stimulation in the anaesthetised cat","volume":"125","author":"Bulmer","year":"1998","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.molmed.2025.08.009_bb0550","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/sj.bjp.0704842","article-title":"Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels","volume":"137","author":"Akerman","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.molmed.2025.08.009_bb0555","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/cvr\/cvab155","article-title":"Neuronal nitric oxide synthase regulates regional brain perfusion in healthy humans","volume":"118","author":"O\u2019Gallagher","year":"2022","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.molmed.2025.08.009_bb0560","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1161\/CIRCULATIONAHA.107.744540","article-title":"Neuronal nitric oxide synthase regulates basal microvascular tone in humans in vivo","volume":"117","author":"Seddon","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.molmed.2025.08.009_bb0565","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1097\/HJH.0b013e32832e8ddf","article-title":"Control of systemic and pulmonary blood pressure by nitric oxide formed through neuronal nitric oxide synthase","volume":"27","author":"Toda","year":"2009","journal-title":"J. Hypertens."},{"key":"10.1016\/j.molmed.2025.08.009_bb0570","article-title":"Effects of fixed dose combination of nNOS inhibition and 5HT agonism on progression of migraine with and without aura","volume":"29","author":"Medve","year":"2009","journal-title":"Cephalalgia"},{"key":"10.1016\/j.molmed.2025.08.009_bb0575","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.sjpain.2012.08.002","article-title":"The nitric oxide synthase inhibitor and serotonin-receptor agonist NXN-188 during the aura phase of migraine with aura: a randomized, double-blind, placebo-controlled cross-over study","volume":"4","author":"Hougaard","year":"2013","journal-title":"Scand J Pain"},{"key":"10.1016\/j.molmed.2025.08.009_bb0580","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1007\/s12035-024-04485-x","article-title":"PSD-95 protein: a promising therapeutic target in chronic pain","volume":"62","author":"Ma","year":"2025","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.molmed.2025.08.009_bb0585","doi-asserted-by":"crossref","first-page":"8872","DOI":"10.1128\/MCB.24.20.8872-8883.2004","article-title":"Neuronal LRP1 functionally associates with postsynaptic proteins and is required for normal motor function in mice","volume":"24","author":"May","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.molmed.2025.08.009_bb0590","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s10194-021-01299-3","article-title":"Repeated oxytocin prevents central sensitization by regulating synaptic plasticity via oxytocin receptor in a chronic migraine mouse model","volume":"22","author":"Wang","year":"2021","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.molmed.2025.08.009_bb0595","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/head.13082","article-title":"Oxytocin and migraine headache","volume":"57","author":"Tzabazis","year":"2017","journal-title":"Headache"},{"key":"10.1016\/j.molmed.2025.08.009_bb0600","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/S0140-6736(25)00194-1","article-title":"Efficacy and safety of nerinetide in acute ischaemic stroke in patients undergoing endovascular thrombectomy without previous thrombolysis (ESCAPE-NEXT): a multicentre, double-blind, randomised controlled trial","volume":"405","author":"Hill","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2025.08.009_bb0605","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/brain\/awn321","article-title":"The vascular theory of migraine \u2013 a great story wrecked by the facts","volume":"132","author":"Goadsby","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.molmed.2025.08.009_bb0610","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1093\/brain\/awn094","article-title":"Migraine headache is not associated with cerebral or meningeal vasodilatation \u2013 a 3T magnetic resonance angiography study","volume":"131","author":"Schoonman","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.molmed.2025.08.009_bb0615","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.18543","article-title":"Effect of vasoactive intestinal polypeptide on development of migraine headaches: a randomized clinical trial","volume":"4","author":"Pellesi","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.molmed.2025.08.009_bb0620","doi-asserted-by":"crossref","first-page":"6151","DOI":"10.3390\/ijms23116151","article-title":"Epigenetic connection of the calcitonin gene-related peptide and its potential in migraine","volume":"23","author":"Fila","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.molmed.2025.08.009_bb0625","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1177\/0333102410391487","article-title":"Epigenetic regulation of the calcitonin gene-related peptide gene in trigeminal glia","volume":"31","author":"Park","year":"2011","journal-title":"Cephalalgia"},{"key":"10.1016\/j.molmed.2025.08.009_bb0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.ynpai.2022.100089","article-title":"Analysis of the DNA methylation pattern of the promoter region of calcitonin gene-related peptide 1 gene in patients with episodic migraine: an exploratory case-control study","volume":"11","author":"Rubino","year":"2022","journal-title":"Neurobiol. Pain"},{"key":"10.1016\/j.molmed.2025.08.009_bb0635","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1177\/0333102417690111","article-title":"Epigenetic DNA methylation changes associated with headache chronification: a retrospective case-control study","volume":"38","author":"Winsvold","year":"2018","journal-title":"Cephalalgia"},{"key":"10.1016\/j.molmed.2025.08.009_bb0640","doi-asserted-by":"crossref","DOI":"10.3390\/nu11112763","article-title":"Is an \u2018epigenetic diet\u2019 for migraines justified? The case of folate and DNA methylation","volume":"11","author":"Fila","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.molmed.2025.08.009_bb0645","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/head.12490","article-title":"Effects of dietary folate intake on migraine disability and frequency","volume":"55","author":"Menon","year":"2015","journal-title":"Headache"},{"key":"10.1016\/j.molmed.2025.08.009_bb0650","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1212\/WNL.50.2.466","article-title":"Effectiveness of high-dose riboflavin in migraine prophylaxis \u2013 a randomized controlled trial","volume":"50","author":"Schoenen","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.molmed.2025.08.009_bb0655","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s10194-015-0576-7","article-title":"DNA methylation of RAMP1 gene in migraine: an exploratory analysis","volume":"16","author":"Wan","year":"2015","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.molmed.2025.08.009_bb0660","doi-asserted-by":"crossref","first-page":"4796","DOI":"10.1093\/brain\/awad390","article-title":"CGRP signalling in migraine: time to look downstream?","volume":"146","author":"Levy","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.molmed.2025.08.009_bb0665","article-title":"Neuropeptides and the nodes of ranvier in cranial headaches","volume":"12","author":"Edvinsson","year":"2021","journal-title":"Front. Physiol."},{"key":"10.1016\/j.molmed.2025.08.009_bb0670","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s10194-024-01753-y","article-title":"CGRP-targeted medication in chronic migraine \u2013 systematic review","volume":"25","author":"Oliveira","year":"2024","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.molmed.2025.08.009_bb0675","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1212\/WNL.0000000000002789","article-title":"The migraine postdrome: an electronic diary study","volume":"87","author":"Giffin","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.molmed.2025.08.009_bb0680","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1212\/01.WNL.0000052998.58526.A9","article-title":"Premonitory symptoms in migraine: an electronic diary study","volume":"60","author":"Giffin","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.molmed.2025.08.009_bb0685","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000010740","article-title":"Central effects of erenumab in migraine patients: an event-related functional imaging study","volume":"95","author":"Ziegeler","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.molmed.2025.08.009_bb0690","doi-asserted-by":"crossref","first-page":"21824","DOI":"10.1038\/s41598-024-72282-6","article-title":"Efficacy of galcanezumab in migraine central sensitization","volume":"14","author":"Danno","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2025.08.009_bb0695","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3390\/neurolint16040051","article-title":"Effects of anti-CGRP monoclonal antibodies on neurophysiological and clinical outcomes: a combined transcranial magnetic stimulation and algometer study","volume":"16","author":"Manganotti","year":"2024","journal-title":"Neurol. Int."},{"key":"10.1016\/j.molmed.2025.08.009_bb0700","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1177\/0333102419844711","article-title":"Peripheral and central nervous system distribution of the CGRP neutralizing antibody [125I] galcanezumab in male rats","volume":"39","author":"Johnson","year":"2019","journal-title":"Cephalalgia"},{"key":"10.1016\/j.molmed.2025.08.009_bb0705","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11916-015-0476-1","article-title":"TEV-48125: a review of a monoclonal CGRP antibody in development for the preventive treatment of migraine","volume":"19","author":"Walter","year":"2015","journal-title":"Curr. Pain Headache Rep."},{"key":"10.1016\/j.molmed.2025.08.009_bb0710","first-page":"1","article-title":"CNS target engagement by the anti-CGRP mAb fremanezumab in the cerebrospinal fluid of healthy volunteers","volume":"43","author":"Rorabaugh","year":"2023","journal-title":"Cephalalgia"},{"key":"10.1016\/j.molmed.2025.08.009_bb0715","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.adc8810","article-title":"A mesothelium divides the subarachnoid space into functional compartments","volume":"379","author":"Mollgard","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.molmed.2025.08.009_bb0720","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.peptides.2010.01.003","article-title":"The design of barriers in the hypothalamus allows the median eminence and the arcuate nucleus to enjoy private milieus: the former opens to the portal blood and the latter to the cerebrospinal fluid","volume":"31","author":"Rodriguez","year":"2010","journal-title":"Peptides"},{"key":"10.1016\/j.molmed.2025.08.009_bb0725","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.physbeh.2007.04.003","article-title":"The sensory circumventricular organs: brain targets for circulating signals controlling ingestive behavior","volume":"91","author":"Fry","year":"2007","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.molmed.2025.08.009_bb0730","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0006-8993(00)03118-8","article-title":"Axon terminals containing CGRP-immunoreactivity form synapses with CRF- and Met-enkephalin-immunopositive neurons in the laterodorsal division of the bed nucleus of the stria terminalis in the rat","volume":"893","author":"Kozicz","year":"2001","journal-title":"Brain Res."},{"key":"10.1016\/j.molmed.2025.08.009_bb0735","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1387044","article-title":"Safety considerations in the treatment with anti-CGRP(R) monoclonal antibodies in patients with migraine","volume":"15","author":"Van Der Arend","year":"2024","journal-title":"Front. Neurol."},{"key":"10.1016\/j.molmed.2025.08.009_bb0740","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1530\/ror.0.0040081","article-title":"Dynamics of immunoglobulins at the feto-maternal interface","volume":"4","author":"Saji","year":"1999","journal-title":"Rev. Reprod."},{"key":"10.1016\/j.molmed.2025.08.009_bb0745","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1210\/jc.2004-1481","article-title":"Evidence for decreased calcitonin gene-related peptide (CGRP) receptors and compromised responsiveness to CGRP of fetoplacental vessels in preeclamptic pregnancies","volume":"90","author":"Dong","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491425002059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491425002059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:52:11Z","timestamp":1775695931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491425002059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":149,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1471491425002059"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2025.08.009","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Migraine: advances in treatment","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2025.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}